The Circulating Cell-free Genome Atlas (CCGA) Study
An observational, longitudinal study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study is being used to discover, train, and validate GRAIL’s products.
View Study
NHS-Galleri Trial
A validation study of Galleri’s clinical and economic performance in the United Kingdom’s National Health System
View Study
PATHFINDER Study
A prospective, interventional, multi-center study evaluating an earlier version of Galleri in clinical practice. PATHFINDER is our first study that returns results to physicians and participants to evaluate how these test results affect diagnostic and care pathways in a screening population.
View Study
PATHFINDER 2 Study
This is a prospective, multi-center interventional study of the Galleri multi-cancer early detection test with return of test results for participants enrolled through healthcare systems in North America.
View Study
REFLECTION Study
An observational study of patients administered the Galleri test.
View Study
STRIVE Study
A prospective, observational, longitudinal, cohort study that enrolled approximately 100,000 women to help validate Galleri in an asymptomatic and intended use population.
View Study
SUMMIT Study
A prospective, observational, longitudinal, cohort study in London, United Kingdom. The study is designed to enroll approximately 13,000 men and women who do not have a cancer diagnosis at the time of enrollment.
View Study
